Related Experiment Video

Updated: Aug 23, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Strategies for inhibition of MDR1 gene expression

Dong Xu1, Hyunmin Kang, Michael Fisher

  • 1Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.

Molecular Pharmacology
|July 22, 2004
PubMed

Insights

Small interfering RNAs (siRNAs) effectively inhibit the multidrug resistance gene MDR1, a key factor in chemotherapy failure. This study demonstrates siRNAs as a viable strategy for overcoming cancer drug resistance.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • RNA Interference

Background:

  • Multidrug resistance (MDR) in cancer, often due to P-glycoprotein overexpression (MDR1 gene), leads to chemotherapy failure.
  • Various strategies exist to modulate cancer-associated gene expression, including antisense oligonucleotides, siRNAs, and artificial transcription factors.

Purpose of the Study:

  • To evaluate the efficacy of small interfering RNAs (siRNAs) in inhibiting MDR1 gene expression.
  • To compare siRNA strategies (chemically synthesized vs. vector-based) with other gene silencing methods.

Main Methods:

  • Chemically synthesized double-stranded RNAs (dsRNAs) and vector-based hairpin siRNAs were tested.
  • NCI/ADR-RES breast carcinoma cells, exhibiting multidrug resistance, were stably transfected with siRNA vectors.
  • Effects on the MDR phenotype were compared with antisense oligonucleotides and transcription factors targeting the MDR1 promoter.

Main Results:

  • Both chemically synthesized and vector-based siRNAs demonstrated the ability to inhibit MDR1 gene expression.
  • Stable transfection of multidrug-resistant cells with hairpin siRNA vectors showed effectiveness in reducing MDR phenotype.
  • siRNA strategies were found to be comparably effective to antisense oligonucleotides and transcription factors.

Conclusions:

  • Small interfering RNAs (siRNAs) represent a potent and effective strategy for inhibiting MDR1 gene expression.
  • siRNA-based approaches offer a promising avenue for overcoming P-glycoprotein-mediated multidrug resistance in cancer.
  • Multiple gene silencing strategies, including siRNAs, show comparable efficacy in targeting MDR1.

More Related Videos

Phage-mediated Delivery of Targeted sRNA Constructs to Knock Down Gene Expression in E. coli08:25

Phage-mediated Delivery of Targeted sRNA Constructs to Knock Down Gene Expression in E. coli

Published on: March 20, 2016

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...